DUBLIN--(BUSINESS WIRE)--The "Non-Invasive Prenatal Testing (NIPT) Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive information about the Non-invasive prenatal testing (NIPT) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Scope
- Extensive coverage of the Non-invasive prenatal testing (NIPT) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Non-invasive prenatal testing (NIPT) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Non-invasive prenatal testing (NIPT) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product's current stage of development, territory and estimated launch date
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Non-invasive prenatal testing (NIPT) Overview
3 Products under Development
3.1 Non-invasive prenatal testing (NIPT) - Pipeline Products by Stage of Development
3.2 Non-invasive prenatal testing (NIPT) - Pipeline Products by Territory
3.3 Non-invasive prenatal testing (NIPT) - Pipeline Products by Regulatory Path
3.4 Non-invasive prenatal testing (NIPT) - Pipeline Products by Estimated Approval Date
3.5 Non-invasive prenatal testing (NIPT) - Ongoing Clinical Trials
4 Non-invasive prenatal testing (NIPT) - Pipeline Products under Development by Companies
4.1 Non-invasive prenatal testing (NIPT) Companies - Pipeline Products by Stage of Development
4.2 Non-invasive prenatal testing (NIPT) - Pipeline Products by Stage of Development
5 Non-invasive prenatal testing (NIPT) Companies and Product Overview
5.1 Agena Bioscience Inc Company Overview
5.2 Amity University Company Overview
5.3 BCML GmbH Company Overview
5.4 BioCeps (Inactive) Company Overview
5.5 Biocept Inc Company Overview
5.6 Biofidelity Ltd Company Overview
5.7 BioFluidica Microtechnologies LLC Company Overview
5.8 Cardiff Oncology Inc Company Overview
5.9 Celula Inc Company Overview
5.10 ChromaCode Inc Company Overview
5.11 Echelon Diagnostics Inc Company Overview
5.12 Elysium Health Inc Company Overview
5.13 Fluxion Biosciences Inc Company Overview
5.14 Helicos BioSciences Corporation Company Overview
5.15 Illumina Inc Company Overview
5.16 INEX Innovate Pte Ltd Company Overview
5.17 Johns Hopkins University Company Overview
5.18 Juno Diagnostics Inc Company Overview
5.19 KellBenx Inc (Inactive) Company Overview
5.20 Laval University Company Overview
5.21 Maastricht University Medical Center Company Overview
5.22 Natera Inc Company Overview
5.23 Oxford Gene Technology Ltd Company Overview
5.24 PerkinElmer Inc Company Overview
5.25 Sequenom Inc Company Overview
5.26 Standard BioTools Inc Company Overview
5.27 StellarGene Technologies Pvt Ltd Company Overview
5.28 The Chaim Sheba Medical Center Company Overview
5.29 The Chinese University of Hong Kong Company Overview
5.30 thromboDx BV Company Overview
5.31 Tufts Medical Center Company Overview
5.32 University of Oxford Company Overview
6 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/7d2dhf
